Uses
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].
Clinical Use
Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis,
psoriatic arthritis, ankylosing spondylitis
Drug interactions
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid.
Metabolism
The majority of IgG elimination occurs via intracellular
catabolism, following fluid-phase or receptor mediated
endocytosis.
References
[1] Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. DOI:
10.1007/s40265-016-0602-3[2] Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. DOI:
10.1007/s40265-016-0602-3[3] Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735. DOI:
10.1002/glia.22637